PHA-022121 low dose

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05396105 (ClinicalTrials.gov)	December 28, 2022	28/4/2022	Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Heredi ...	A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema ...	Hereditary Angioedema;Hereditary Angioedema Type I;Hereditary Angioedema Type II;Hereditary Angioede ...	Drug: PHA-022121 low dose;Drug: PHA-022121 medium dose;Drug: PHA-022121 high dose;Drug: PHA-022121 s ...	Pharvaris Netherlands B.V.	NULL	Recruiting	18 Years	N/A	All	72	Phase 2/Phase 3	United States;Bulgaria;Czechia;France;Germany;Hungary;Spain
2	NCT05047185 (ClinicalTrials.gov)	April 19, 2022	7/9/2021	Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With He ...	A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Eval ...	Hereditary Angioedema;Hereditary Angioedema Type I;Hereditary Angioedema Type II;Hereditary Angioede ...	Drug: PHA-022121 low dose;Drug: PHA-022121 high dose;Drug: Placebo	Pharvaris Netherlands B.V.	NULL	Recruiting	18 Years	75 Years	All	30	Phase 2	United States;Bulgaria;Canada;Germany;Israel;Italy;Poland;Spain;United Kingdom

First Previous1Next Last